PMC:7376974 / 4565-6492
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T7 | 456-461 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T8 | 482-495 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
| T9 | 711-716 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T10 | 806-811 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T11 | 941-945 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T12 | 1487-1490 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 482-495 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 50 | 1502-1519 | Species | denotes | influenza viruses | Tax:11308 |
| 51 | 1055-1067 | Chemical | denotes | nanovaccines | |
| 52 | 540-549 | Disease | denotes | infection | MESH:D007239 |
| 53 | 1307-1315 | Disease | denotes | toxicity | MESH:D064420 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T20 | 540-549 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T21 | 1492-1496 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T22 | 1502-1511 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T35 | 439-447 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T36 | 456-461 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T37 | 482-495 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
| T38 | 505-512 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focused |
| T39 | 674-679 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T40 | 711-721 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells will |
| T41 | 806-816 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells will |
| T42 | 885-893 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T43 | 941-945 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T44 | 962-972 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
| T45 | 1369-1377 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T46 | 1512-1519 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T20 | 72-83 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
| T21 | 95-111 | Chemical | denotes | antiviral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T22 | 277-286 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T23 | 429-438 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T24 | 605-616 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
| T25 | 847-856 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T26 | 1609-1618 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T27 | 1649-1660 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
| T28 | 1672-1688 | Chemical | denotes | antiviral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T29 | 1910-1926 | Chemical | denotes | antiviral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T31151 | 689-710 | http://purl.obolibrary.org/obo/GO_0051701 | denotes | interaction with host |
| T10 | 885-914 | http://purl.obolibrary.org/obo/GO_1903902 | denotes | activity in viral replication |
| T11 | 897-914 | http://purl.obolibrary.org/obo/GO_0019079 | denotes | viral replication |
| T12 | 897-914 | http://purl.obolibrary.org/obo/GO_0019058 | denotes | viral replication |
| T13 | 962-991 | http://purl.obolibrary.org/obo/GO_0002253 | denotes | activation of immune response |
| T14 | 976-991 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T29 | 0-112 | Sentence | denotes | In this review, we will critically analyze different strategies for the application of HNMs as antiviral agents. |
| T30 | 113-221 | Sentence | denotes | The rational and the synthetic strategies will be highlighted and correlated to different relevant examples. |
| T31 | 222-332 | Sentence | denotes | Particular attention will be paid on the mechanisms of antiviral action and on HNM applicability and efficacy. |
| T32 | 333-496 | Sentence | denotes | For the sake of clarity, this review is divided into three parts, namely: blocking viral entry, antiviral activity in host cells, and stimulation of immune system. |
| T33 | 497-550 | Sentence | denotes | We have focused on the different stages of infection. |
| T34 | 551-735 | Sentence | denotes | In the section dedicated to blocking viral entry, the application of HNMs for surface disinfection and inactivation of the virus prior to interaction with host cells will be described. |
| T35 | 736-955 | Sentence | denotes | Subsequently, the interaction of HNMs after internalization into host cells will be addressed, stressing their antiviral delivery features and their activity in viral replication blockage, leading to host cell survival. |
| T36 | 956-1097 | Sentence | denotes | Then, activation of immune response induced by HNMs, triggering the innate and the adaptive (e.g., nanovaccines) immunity, will be presented. |
| T37 | 1098-1265 | Sentence | denotes | The different adopted strategies will be correlated to the nanomaterial core (e.g., composition, size, shape) and surface (e.g., chemistry, surface charge) properties. |
| T38 | 1266-1521 | Sentence | denotes | Finally, limits (e.g., unknown long-term toxicity), advantages (e.g., high and wide spectrum virucidal activity), and perspectives will be discussed with particular attention to the applications in viral pandemics (e.g., HIV, SARS, and influenza viruses). |
| T39 | 1522-1628 | Sentence | denotes | This review is addressed to material and biomaterials scientists who are interested in antiviral research. |
| T40 | 1629-1793 | Sentence | denotes | We acknowledge that application of HNMs as antiviral agents is still in the early stages; however, we believe that the research on this topic is going to grow soon. |
| T41 | 1794-1927 | Sentence | denotes | Thus, with this contribution we genuinely hope to inspire researchers in the preparation of smart and efficient HNM antiviral agents. |